SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1538 7933 srt2:(2005-2009)"

Sökning: L773:1538 7933 > (2005-2009)

  • Resultat 1-10 av 109
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  • Blomback, B (författare)
  • Travels with fibrinogen
  • 2006
  • Ingår i: Journal of thrombosis and haemostasis : JTH. - : Elsevier BV. - 1538-7933 .- 1538-7836. ; 4:8, s. 1653-1660
  • Tidskriftsartikel (refereegranskat)
  •  
6.
  •  
7.
  •  
8.
  • Borel-Derlon, A., et al. (författare)
  • Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin (R)): a prospective study of 50 patients
  • 2007
  • Ingår i: Journal of Thrombosis and Haemostasis. - : Elsevier BV. - 1538-7933 .- 1538-7836. ; 5:6, s. 1115-1124
  • Tidskriftsartikel (refereegranskat)abstract
    • Background and objectives: A plasma-derived von Willebrand factor (VWF) concentrate with low factor VIII (FVIII) content was specifically developed to treat von Willebrand disease (VWD). Efficacy and safety were investigated by merging the results of two comparable protocols conducted prospectively in 5 European and 12 French centers. Methods and results: Fifty patients with clinically severe VWD (72% had VWF ristocetin cofactor activity less than 10 IU dL(-1) and 46% had FVIII < 20 IU dL(-1)) were treated with the concentrate as the only therapy, except for clinical situations requiring a priming dose of FVIII to rapidly correct an intrinsic coagulation defect. A total of 139 spontaneous bleeding episodes were treated; only 53 (38%) needed a concomitant FVIII dose. Outcome was excellent or good in 89% of the episodes. Forty-four patients underwent 108 surgical or invasive procedures. Outcome was excellent or good in 95 scheduled procedures (only VWF was infused) and 13 emergency procedures (a priming FVIII dose was co-administered with the first VWF infusion). There were no thrombotic complications and none of the 18 patients with type 3 VWD developed anti-VWF or anti-FVIII antibodies. Conclusions. This concentrate safely and effectively provides hemostasis in patients with clinically severe VWD.
  •  
9.
  • Budde, U, et al. (författare)
  • Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD)
  • 2008
  • Ingår i: Journal of Thrombosis and Haemostasis. - : Elsevier BV. - 1538-7933 .- 1538-7836. ; 6:5, s. 762-771
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Type 1 von Willebrand disease (VWD) is a congenital bleeding disorder characterized by a partial quantitative deficiency of plasma von Willebrand factor (VWF) in the absence of structural and/or functional VWF defects. Accurate assessment of the quantity and quality of plasma VWF is difficult but is a prerequisite for correct classification. Objective: To evaluate the proportion of misclassification of patients historically diagnosed with type 1 VWD using detailed analysis of the VWF multimer structure. Patients and methods: Previously diagnosed type 1 VWD families and healthy controls were recruited by 12 expert centers in nine European countries. Phenotypic characterization comprised plasma VWF parameters and multimer analysis using low- and intermediate-resolution gels combined with an optimized visualization system. VWF genotyping was performed in all index cases (ICs). Results: Abnormal multimers were present in 57 out of 150 ICs; however, only 29 out of these 57 (51%) had VWF ristocetin cofactor to antigen ratio below 0.7. In most cases multimer abnormalities were subtle, and only two cases had a significant loss of the largest multimers. Conclusions: Of the cases previously diagnosed as type 1 VWD, 38% showed abnormal multimers. Depending on the classification criteria used, 22 out of these 57 cases (15% of the total cohort) may be reclassified as type 2, emphasizing the requirement for multimer analysis compared with a mere ratio of VWF functional parameters and VWF:Ag. This is further supported by the finding that even slightly aberrant multimers are highly predictive for the presence of VWF mutations.
  •  
10.
  • Castaman, G., et al. (författare)
  • Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study
  • 2006
  • Ingår i: Journal of Thrombosis and Haemostasis. - : Elsevier BV. - 1538-7933 .- 1538-7836. ; 4:10, s. 2164-2169
  • Tidskriftsartikel (refereegranskat)abstract
    • Objectives: We undertook an international, multicenter study to describe the clinical picture and to estimate the bleeding risk in a group of obligatory carriers of type 3 von Willebrand disease (VWD). Patients and methods: Obligatory carriers (OC) of type 3 VWD were identified by the presence of offspring with type 3 VWD or by being an offspring of a type 3 patient. Normal controls were age- and sex-matched with the obligatory carriers. A physician-administered standardized questionnaire was used to evaluate hemorrhagic symptoms at presentation. A score system ranging from 0 (no symptom) to 3 (hospitalization, replacement therapy, blood transfusion) was used to quantitate bleeding manifestations. Odds ratios were computed for each symptom. Results: Ten centers participated to the study, enrolling a total of 35 type 3 VWD families, with 70 OC. A total of 215 normal controls and 42 OC for type 1 VWD were also included. About 40% of type 3 OC had at least one bleeding symptom compared to 23% of normal controls and 81.8% of type 1 OC (P < 0.0001 by chi-squared test), showing that type 3 OC clearly represent a distinct population from type 1 OC. The clinical situations associated with an increase of bleeding risk in type 3 OC were epistaxis [odds ratio 3.6; 90% confidence intervals (CI) 1.84-21.5], cutaneous bleeding (odds ratio 5.5; 90% CI 2.5-14.1) and postsurgical bleeding (odds ratio 16.3; 90% CI 4.5-59). The severity of bleeding score correlated with the degree of factor (F) VIII reduction in plasma. Conclusions: OC for type 3 VWD represent a distinctive population from type 1 OC. These patients, however, present with more frequent bleeding symptoms in comparison to normal controls, especially in case of significantly low FVIII. Desmopressin and/or tranexamic acid might be useful to prevent or treat bleeding in these cases.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 109
Typ av publikation
tidskriftsartikel (81)
konferensbidrag (24)
forskningsöversikt (3)
annan publikation (1)
Typ av innehåll
refereegranskat (78)
övrigt vetenskapligt/konstnärligt (31)
Författare/redaktör
Lethagen, Stefan (8)
Schulman, S (7)
Castaman, G. (7)
Rodeghiero, F. (7)
Renne, T (6)
Goudemand, J. (6)
visa fler...
Holmberg, Lars (5)
Federici, A. B. (5)
Wallen, H (5)
Mobarrez, F (5)
Eriksson, Bengt I., ... (5)
Ingerslev, J. (5)
Mazurier, C. (5)
Stenflo, Johan (5)
Budde, U (5)
Schneppenheim, R (5)
Batlle, J (5)
Meyer, D (5)
Berntorp, Erik (4)
Bergqvist, David (4)
Blomback, M (4)
Li, N (4)
Goodeve, A. (4)
Peake, I. (4)
Antovic, A (4)
Pasi, J (4)
Tosetto, A. (4)
Eikenboom, J (4)
Habart, D (4)
Vorlova, Z (4)
Hill, F (4)
Federici, AB (4)
Lindqvist, P. G. (4)
Hjemdahl, P (3)
Siegbahn, Agneta (3)
Jern, Christina, 196 ... (3)
Hedner, Ulla (3)
Dahl, O E (3)
Holmstrom, M (3)
Hamsten, A (3)
Silveira, A. (3)
Bremme, K (3)
Srivastava, A (3)
Lubenow, Norbert (3)
Astermark, Jan (3)
He, S (3)
Greinacher, A. (3)
Scharrer, I. (3)
Kalebo, P. (3)
Eichler, P (3)
visa färre...
Lärosäte
Karolinska Institutet (43)
Lunds universitet (42)
Uppsala universitet (18)
Göteborgs universitet (10)
Linköpings universitet (5)
Umeå universitet (2)
visa fler...
Högskolan Kristianstad (1)
Kungliga Tekniska Högskolan (1)
Mittuniversitetet (1)
Chalmers tekniska högskola (1)
Linnéuniversitetet (1)
visa färre...
Språk
Engelska (109)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (56)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy